AfoliOpen Afoli →

Prucalopride

Prucalopride is an approved active ingredient.

Open in Afoli Medicines →

Chemical compound

Informational only — not medical advice. Ask a doctor or pharmacist; never change a dose on your own.

What it is used for

MOTEGRITY ® is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. MOTEGRITY is a serotonin-4 (5-HT 4 ) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults.

US label

Resolor is indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief.

EMA

How it works

Common side effects

Most common adverse reactions (≥2%) are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue.

US label

Who should not take it

MOTEGRITY is contraindicated in patients with: A history of hypersensitivity to MOTEGRITY. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed.

US label

Pregnancy and breastfeeding

Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to MOTEGRITY during pregnancy.

Excerpts from the US prescribing label (public domain), copied without changes.

Brand names

United States

Motegrity

European Union

Resolor

Canada

Apo-Prucalopride · Jamp Prucalopride · Nra-Prucalopride · Resotran

Approval status

US Food and Drug Administration
prescription · since 2018
European Medicines Agency
authorised · since 2009
Health Canada
prescription · marketed
First approval anywhere
2009

Codes

ATC
A06AX05
RxNorm CUI
2107310
ChEMBL
CHEMBL117287
PubChem CID
3052762
UNII
0A09IUW5TP
Wikidata
Q68484

Frequently asked questions

What is Prucalopride used for?

Prucalopride is used for: Constipation.

What are the brand names of Prucalopride?

Brand names of Prucalopride include Motegrity, Resolor, Apo-Prucalopride, Jamp Prucalopride, Nra-Prucalopride, and Resotran.

Medicines in the same class

Sources and licences

Updated November 15, 2026